Excerpts

Figure 5 B shows a statistical trend between a lower ADC value and PR or SD patients ( p = 0.07).

Expression of miRNA-221 was not correlated with OS in the present patient cohort, however, in patients without neoadjuvant treatment miRNA-221 positive tumors showed a strong trend towards shortened OS ( p = 0.070) with a median OS of 64.0 months in miRNA-221 negative patients (95%CI not calculable) compared to a median OS of 22.1 month (95%CI 13.3–30.8 months).

Although alterations in PI3K, TGF-Beta, and RTK/RAS pathways were not statistically significant, borderline significance was observed in genes related to these pathways, including EGFR ( p = 0.07), FGFR1 ( p = 0.05), FGFR2 ( p = 0.05), and PTPN11 ( p = 0.05) in the PI3K pathway and SMAD4 ( p = 0.08) in the TGF-Beta pathway.

Additionally, though borderline significant, in patients that were diagnosed with pancreatic pathology at the age of 65 years or younger, COPD also correlated with IPMN (OR 4.4, 95% CI 0.98–19.79, p = 0.07).

The FIGO stage was found to be of borderline significance ( p = 0.070, Figure 4 C).

Other hemodynamic parameters showed only borderline significance (cumulative time of reduced heart rate: p = 0.0706; mean systolic blood pressure during surgery: p = 0.0844; oxygen saturation: p = 0.0719; mean heart rate p = 0.0937).

Tumor necrosis factor alpha (TNFα) levels were higher in BCW12OFS mice compared to BCW0 mice ( p = 0.009) and approached significance compared to BCW12 ( p = 0.071) ( Figure 11 C).

There was a statistical trend in OS ( p = 0.071) and PFS ( p = 0.053) for both cohorts.

Despite most of the samples with high expression of ID4 were from patients older than 50 (73.5%), this association was marginally significant ( p = 0.071).

Regarding the EFS, none of the analyzed factors remained significant in the multivariate analysis but PLS3 had the strongest impact and was borderline significant ( p = 0.071, HR 1.39 (CI 0.97–2.09)).

The analysis to recognize a predictive prognostic value for miRNA dysregulation showed a trend toward significance (overexpression of miRNA–221, p = 0.071).

Dysphagia grade III six months after treatment showed a trend toward worse survival ( p = 0.071).

The LDHA expression of A-498 was also higher than that of UOK262 tumors, with a p -value approaching significance (400 ± 51% vs. 280 ± 43%, p = 0.071) ( Figure 3 B). 2.3.

An analysis of OS showed a trend toward statistical significance with decreased TTAC (HR 1.004 [0.9997–1.0084]; p = 0.071).

These responders demonstrated a clear trend toward longer OS compared with the non-responders (36.7 vs. 21.5 months, p = 0.071).

The results showed a trend of increased ROS levels (two-tailed unpaired t -test, p = 0.0715) in nerolidol-treated cells when compared to control cells ( Figure S2A ).

When adjusted for confounders, the use of the kit was associated with a nearly significant survival benefit: hazard ratio 0.85 (95% confidence interval: 0.71-1.02, p = 0.0716).

The presence of a pathogenic somatic myeloid mutation was not a risk factor for a CVE for patients receiving imatinib at the time of the CVE (OR 1.9, p = 0.409) but was of borderline significance for patients receiving a 2G-TKI at the time of the CVE (OR 3.11, p = 0.072; Supplementary Table S3 ).

IHC analysis for p-MAPK, a downstream target of FGFR4, in RMS559 tumors found that p-MAPK was suppressed in mice treated with futibatinib compared to vehicle (approaching significance, p = 0.072; Figure A6 ).

Despite a strong trend in the same direction, CTNNB1 mutations showed no statistically significant association with higher hazard ratio (HR) of PSA progression (HR 2.12, p = 0.072) [ 24 ].

An improvement in OS was also noted to be trending towards significance with the use of Osimertinib compared to erlotinib/gefitinib (not reached vs. 20.9 months, p = 0.0725) [ 27 ].

In addition, under criterion 1, nodal status was significant, and tumor size demonstrated a trend toward significance ( p = 0.073).

In univariate analysis, patients with MTS-like cancers showed a trend toward improved survival compared to those with other malignancies ( p = 0.073; Supplementary Table S9 and Supplementary Figure S4A ), although this did not reach statistical significance and was not confirmed in multivariable Cox regression (HR 1.2, 95% CI 0.53–2.7; Figure 5 A).

There was a borderline significant association between neoantigen expression and the HER2 status ( p = 0.073).

Bone metastasis showed a trend toward statistical significance (HR = 2.283, 95% CI: 0.927–5.624, p = 0.073).